Eli Lilly's manufacturing expansion secures GLP-1 lead
Eli Lilly's massive infrastructure spending ensures it can monetize its dominant position in GLP-1 obesity treatments while funding pipeline diversification.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.